➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Mallinckrodt
AstraZeneca
Express Scripts
Boehringer Ingelheim

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

SYMPAZAN Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Sympazan patents expire, and when can generic versions of Sympazan launch?

Sympazan is a drug marketed by Aquestive and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and sixty-one patent family members in eighteen countries.

The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the clobazam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sympazan

A generic version of SYMPAZAN was approved as clobazam by AMNEAL on October 22nd, 2018.

  Try Before You Buy

US Patents and Regulatory Information for SYMPAZAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 RX Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 RX Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 RX Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 RX Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SYMPAZAN

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2014144241   Try Before You Buy
World Intellectual Property Organization (WIPO) 2007075422   Try Before You Buy
Australia 2002362772   Try Before You Buy
Denmark 1463491   Try Before You Buy
Russian Federation 2015143647   Try Before You Buy
Mexico 2015013184   Try Before You Buy
European Patent Office 2428206   Try Before You Buy
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.